Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology

Drug Metabolism and Disposition

Volumn 39, Issue 4, 2011, Pages 603-609

  El Komy, Mohammed H ^a   Widness, John A ^b   Veng Pedersen, Peter ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN RECEPTOR;

ADULT ANIMAL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; ENDOCYTOSIS; INTERNALIZATION; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; SHEEP;

ANIMALS; AREA UNDER CURVE; BUSULFAN; DRUG INTERACTIONS; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; MODELS, BIOLOGICAL; MODELS, THEORETICAL; MYELOABLATIVE AGONISTS; POLYETHYLENE GLYCOLS; RADIOLIGAND ASSAY; SHEEP;

OVIS ARIES;

EID: 79952825195     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036236     Document Type: Article

References (39)

1. Al-Huniti NH, Widness JA, Schmidt RL, and Veng-Pedersen P (2005) Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis. J Pharmacokinet Pharmacodyn 32:359-376. (Pubitemid 41742189)
2. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, and Noguchi CT (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 91:3974-3978. (Pubitemid 24139555)
3. Brandt M, Lanzendorfer M, Frische J, Haselbeck A, and Jarsch M (2006) Different receptor binding activity of CERA (continuous erythropoietin receptor activator) compared with epoetin β determined by surface plasmon resonance and competition assay on UT-7 cells. Nephrol Dial Transplant 21:9.
4. Carlini RG, Alonzo EJ, Dominguez J, Blanca I, Weisinger JR, Rothstein M, and Bellorin-Font E (1999) Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 55:546-553. (Pubitemid 29082880)
5. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, and Widness JA (2001) Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 298:820-824. (Pubitemid 32673436)
6. Chapel SH, Veng-Pedersen P, Schmidt RL, and Widness JA (2000) A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep. J Pharmacol Exp Ther 295:346-351.
7. Fishbane S, Pannier A, Liogier X, Jordan P, Dougherty FC, and Reigner B (2007) Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol 47:1390-1397. (Pubitemid 47624598)
8. Gibiansky L, Gibiansky E, Kakkar T, and Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35:573-591.
9. Gross AW and Lodish HF (2006) Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 281:2024-2032. (Pubitemid 43845790)
10. Haselbeck A, Tare N, and Pill J (2002) Pre-clinical pharmacokinetics and pharmacodynamics of CERA (continuous erythropoiesis receptor activator) indicate a superior new therapy for anemia. Blood 100:228a.
11. Hutchinson MF and de Hoog FR (1985) Smoothing noisy data with spline functions. Numerische Mathematik 47:99-106.
12. Jarsch M, Brandt M, Lanzendörfer M, and Haselbeck A (2008) Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 81:63-69. (Pubitemid 350124538)
13. Jelkmann W, Bohlius J, Hallek M, and Sytkowski AJ (2008) The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 67:39-61.
14. Jin F and Krzyzanski W (2004) Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS PharmSci 6:E9.
15. Juul SE, Yachnis AT, and Christensen RD (1998) Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 52:235-249. (Pubitemid 28548695)
16. Kupcová V, Sperl J, Pannier A, Jordan P, Dougherty FC, and Reigner B (2008) The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A. Curr Med Res Opin 24:1943-1950.
17. Locatelli F and Del Vecchio L (2008) Optimizing the management of renal anemia: challenges and new opportunities. Kidney Int Suppl 74:S33-S37.
18. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, and Reigner B (2006) Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 1:1211-1215.
19. Mager DE and Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting targetmediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532. (Pubitemid 34289541)
20. Mager DE and Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22:1589-1596. (Pubitemid 41355898)
21. Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, and Jusko WJ (2003) Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther 306:262-270. (Pubitemid 36734381)
22. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, and Kim SU (2001) Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 60:386-392. (Pubitemid 32274054)
23. Nestorov I (2003) Whole body pharmacokinetic models. Clin Pharmacokinet 42:883-908.
24. Nestorov IA, Aarons LJ, Arundel PA, and Rowland M (1998) Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 26:21-46. (Pubitemid 28429460)
25. Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, and Noguchi CT (2000) Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 275:39754-39761. (Pubitemid 32059005)
26. Sawyer ST, Krantz SB, and Goldwasser E (1987) Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem 262:5554-5562.
27. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, and PROTOS Study Investigators (2007) Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2:637-646.
28. Thygesen P, Macheras P, and Van Peer A (2009) Physiologically-based PK/PD modelling of therapeutic macromolecules. Pharm Res 26:2543-2550.
29. Upton RN (2008) Organ weights and blood flows of sheep and pig for physiological pharmacokinetic modelling. J Pharmacol Toxicol Methods 58:198-205.
30. Pedersen PV (1977) Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokinet Biopharm 5:513-531.
31. Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, and Widness JA (2003) A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep. J Pharmacol Exp Ther 306:532-537. (Pubitemid 36886151)
32. Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, and Widness JA (2004) Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharm Drug Dispos 25:149-156. (Pubitemid 38765288)
33. Veng-Pedersen P, Freise KJ, Schmidt RL, and Widness JA (2008) Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin. J Pharm Pharmacol 60:1321-1334.
34. Veng-Pedersen P, Widness JA, Wang J, and Schmidt RL (1997) A tracer interaction method for nonlinear pharmacokinetics analysis: application to evaluation of nonlinear elimination. J Pharmacokinet Biopharm 25:569-593. (Pubitemid 28355711)
35. Walrafen P, Verdier F, Kadri Z, Chrétien S, Lacombe C, and Mayeux P (2005) Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 105:600-608. (Pubitemid 40070742)
36. Weiss M and Roberts MS (1996) Tissue distribution kinetics as determinant of transit time dispersion of drugs in organs: application of a stochastic model to the rat hindlimb. J Pharmacokinet Biopharm 24:173-196. (Pubitemid 26300484)
37. Widness JA, Schmidt RL, Veng-Pedersen P, Modi NB, and Sawyer ST (1992) A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studies. J Lab Clin Med 119:285-294.
38. 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep. J Pharmacol Exp Ther 279:1205-1210.
39. Woo S, Krzyzanski W, and Jusko WJ (2007) Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn 34:849-868. (Pubitemid 350165278)